Brought to you by 
CoTherix gets acquired by Actelion for $420mm in cash
04 Dec 2006
Executive Summary
Actelion has agreed to acquire fellow cardiovascular therapeutics developer CoTherix for $420mm in cash. CoTherix shareholders will receive $13.50 (a 37% premium) for each share they own.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CoTherix gets acquired by Actelion for $420mm in cash
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice